CTMX CytomX Therapeutics Inc Gross Profit Rate

CytomX Therapeutics (CTMX) develops B2B solutions for the oncology market using tumor-activated drug technology. Innovative "smart" antibodies minimize therapy toxicity for healthy tissues. Robust patent protection and strict FDA regulations create a strong barrier to entry for competitors. The gross margin coefficient confirms these fundamental trends, with the metric currently standing at 91.30.
Comprehensive metric breakdowns and analytics for CytomX Pharma (CTMX)

To objectively assess the operational efficiency of CytomX Therapeutics (CTMX), investors must analyze the company's ability to convert revenue into gross profit. The net gross margin trend reflects the share of income minus direct costs, which, in the context of licensing payments from BMS and Amgen, demonstrates the scalability of the Probody platform and the potential for long-term growth in return on equity.